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Cardiomyopathies are myocardial disorders in which the heart
muscle is structurally and functionally abnormal in the absence
of coronary artery disease, hypertension, valvular disease and
congenital heart disease, sufﬁcient to cause the observed
myocardial abnormality. They are classiﬁed into a number of
morphological and functional phenotypes that can be caused
by genetic and non-genetic mechanisms. A few key themes have
been dominant in 2010–11, foremost of which are the use (and
interpretation) of increasingly sophisticated genetic analyses
and the use of new non-invasive imaging techniques to study
clinical phenotypes. There were few advances in treatment re-
ported and it remains clear that there is a need for properly con-
ducted randomised trials in all forms of cardiomyopathy.
2. Hypertrophic cardiomyopathy (HCM)
HCM is deﬁned by the presence of myocardial hypertrophy
unexplained by loading conditions. It is a genetic disorder pre-
dominantly caused by mutations in sarcomere protein genes,
but other genetic diseases, including metabolic disorders such
as Anderson–Fabry disease, account for a substantial minority
of cases.1
The literature over the past year illustrates the continued
importance of conventional diagnostic tools such as ECG
and echocardiography in the diagnosis of HCM, but various
reﬁnements using different technical approaches, such as defor-
mation imaging and 3D echo, were reported. Perhaps the most
important advance has been the use of cardiac MRI. Two as-
pects were prominent: the ability of cardiomagnetic resonance
(CMR) to detect myocardial segments ‘invisible’ to echocardi-
ography (e.g., posterior septum and apex) and probably more
importantly, the ability to image myocardial scar using gado-
linium enhancement. Numerous papers have examined the pat-
tern and distribution of scar and its relation to clinical
presentation and prognosis.2–4 Most data suggest that the pres-
ence of scar is predictive of heart failure rather than sudden car-
diac death, but larger unbiased cohort studies are required.
Methods to detect diffuse ﬁbrosis are likely to be even more
important as this probably develops at an early stage of the dis-
ease and represents an important therapeutic target.5,6
3. Management
Many patients with HCM experience premature death or have
decades of poor health. The current state-of-the art in the man-
agement of each patient with HCM focuses on three aspects of
the disease: identiﬁcation of individuals who are at increased
risk of sudden cardiac death and thus might beneﬁt from
implantable cardioverter-deﬁbrillator (ICD) treatment; relief
of left ventricular (LV) outﬂow tract obstruction and palliation
of limiting symptoms caused by systolic or diastolic dysfunction.
In all three areas, treatments remain suboptimal, particularly in
the prevention of progressive heart failure. Potential beneﬁts ofpresymptomatic diagnoses in affected family members, largely
justiﬁed on the basis of sudden death prevention, are also an
emerging theme in many papers.7,8
4. Relief of LV outﬂow obstruction
Several meta-analyses comparing the results of septal myec-
tomy with septal alcohol ablation have been published.9–12 In
general, these studies show that alcohol septal ablation is asso-
ciated with broadly similar mortality rates and improvements in
functional status to those reported for surgical treatment, albeit
with a higher risk of permanent pacemaker implantation and
greater postintervention outﬂow tract gradient. Some series
have shown an excess of deaths after alcohol ablation, resulting
in cautionary comments about the safety of this procedure.10
The search for alternative treatments for outﬂow tract obstruc-
tion also continues with reports of radiofrequency ablation of
the septum and reappraisal of dual chamber atrioventricular
sequential pacing.13–15 In the absence of a randomised compar-
ison, the controversies about the relative strengths and weak-
nesses of each of these treatments will continue. Currently,
invasive treatment of LV outﬂow obstruction is recommended
only in patients with drug-refractory symptoms.
5. Sudden cardiac death
In contemporary practice, a small number of clinical risk
markers are used in aggregate to predict the probability of sud-
den cardiac death and the need for ICDs.16,17 While remaining
valid, current approaches have important limitations. In par-
ticular, many patients receiving ICDs for primary prevention
never require device intervention, are exposed to risks of de-
vice-related complications and remain at risk of premature
death from thromboembolic stroke and progressive heart fail-
ure.18 In addition, while the genetic causes of HCM in children
are similar to those in adults,19 conventional risk prediction
algorithms may not apply to paediatric populations.20 Further
data on risk prediction and randomised trials of interventions
that might prevent disease progression are clearly necessary.
6. Refractory symptomatic HCM
It has been hypothesised that excessive sarcomeric energy con-
sumption is important in the pathophysiology of HCM and
other heart muscle diseases. The mechanism of this energetic
disturbance is not understood, but high energy phosphate
ratios are reduced in patients with mutations in sarcomere
proteins and little or no hypertrophy, suggesting that energy
deﬁciency is a fundamental characteristic of the HCM pheno-
type. As disturbance of fatty acid metabolism is one the key
drivers of inefﬁcient energy use in the failing heart,21 perhexil-
ine, an inhibitor of mitochondrial fatty acid uptake, was used
to treat exertional symptoms in a randomised placebo-con-
trolled trial. Perhexiline improved symptoms, exercise capacity
and diastolic function during exercise in symptomatic patients
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drugs might be of use in some patients.22
7. Family screening
Recently published cost–beneﬁt analyses comparing genetic
and clinical screening strategies provide an economic argument
for the use of genetic testing in family screening.78 However, the
published models are based on the assumption that risk-predic-
tion algorithms developed and validated in populations at rela-
tively high risk (largely comprising proband patients) apply
equally to cohorts at lower baseline risk (Moons et al., unpub-
lished data). In addition, confounders such as family size, dis-
ease penetrance, genetic variants of uncertain signiﬁcance and
the relatively high frequency of compound heterozygosity are
largely unaccounted for in current cost-efﬁcacy models. Pro-
spective evaluation of different screening strategies is necessary.
8. Arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
a genetic heart muscle disease characterised histologically by
cardiomyocyte loss and replacement by ﬁbrous or ﬁbrofatty
tissue, and clinically by arrhythmia, sudden cardiac death
and heart failure. In many people, the disease is caused by
mutations in genes that encode components of the intercalated
disc of cardiomyocytes.23 Clinically, ARVC is difﬁcult to diag-
nose, requiring integration of data from family members, ge-
netic testing, electrocardiography and imaging techniques.24
The major management problems in ARVC are prevention
of sudden cardiac death and treatment of symptomatic
arrhythmia and heart failure.
9. Aetiology
Systematic family studies have shown that ARVC is inherited
in up to 50% of cases as an autosomal dominant trait with
incomplete penetrance and variable clinical expression. To
date, most studies have shown that the majority of familial
cases are caused by heterozygous mutations in genes encoding
desmosomal proteins, but other genes have been implicated
including transforming growth factor b3 and transmembrane
protein 43 (TMEM43), a cytoplasmic membrane protein.23–25
Over the past year, further evidence of genetic heterogeneity
has been demonstrated by the discovery of pathogenic muta-
tions in desmin, an intermediate ﬁlament protein, and
titin.26–28 In addition, studies continue to report complex ge-
netic status in many patients with multiple variants in different
desmosomal genes.29 The presence of multiple mutations ap-
pears to increase the severity of the clinical phenotype, but also
poses a challenge for the interpretation of genetic testing, par-
ticularly with regard to variants that may occur in normal pop-
ulations which do not cause disease in themselves, but might
conceivably alter disease susceptibility in the presence of other
genetic or environmental factors.
10. Diagnostic criteria
As in other heart muscle diseases, current diagnostic paradigms
for ARVC represent the latest iteration of a scientiﬁc and clin-
ical narrative that began with the study of severe cases present-ing with sudden cardiac death or ventricular arrhythmia.
Pathological examination of postmortem specimens from these
advanced forms of the disease was used to establish histological
hallmarks of the disease––namely, ﬁbrofatty replacement, aneu-
rysm formation and right ventricular dilatation. Thereafter,
standard clinical tools such as ECG, ventriculography, echocar-
diography and latterly cardiacMRI have been used to diagnose
ever more subtle manifestations of this histological phenotype.
Recognition that the disease is a familial trait caused by muta-
tions in genes that code for proteins of the intercalated disc, has
added to this complexity.30 A rationalisation of these different
aspects of the disease formed the basis for modiﬁed diagnostic
criteria published simultaneously in Circulation and the Euro-
pean Heart Journal in 2010.24 This important paper has already
deﬁned future clinical and scientiﬁc enquiry, and evidence from
families suggests that the sensitivity and speciﬁcity of the crite-
ria have improved.31,32 Nevertheless, the greater emphasis on
quantiﬁcation and genotyping is already posing signiﬁcant
diagnostic and management challenges. For example, athletic
training alone may result in a phenotype that fulﬁls criteria in
the absence of genetic evidence for the disease33 and ECG
criteria may also show considerable variability with time.3411. Prevention of sudden death
In spite of the reputation of ARVC as a major cause of sudden
cardiac death, prospective data on the risk of sudden death in
unselected populations and its prevention are surprisingly few.
Current AHA/ACC/ESC 2006 guidelines for the management
of patients with ventricular arrhythmias and the prevention of
sudden cardiac death recommend ICD implantation in pa-
tients with ARVC who have documented sustained ventricular
tachycardia (VT) or ventricular ﬁbrillation (VF) and in those
who are receiving optimal medical treatment with reasonable
expectation of survival with a good functional status for more
than 1 year. Recommendations in patients without these fea-
tures are necessarily more speculative. Retrospective analyses
have identiﬁed a number of possible predictors of adverse out-
come in probands, including early age of onset of symptoms,
participation in competitive sports, a malignant family history,
severe right ventricular dilatation, LV involvement, syncope,
episodes of ventricular arrhythmias and increased QRS disper-
sion on 12-lead ECG. In 2010, Corrado et al. published a study
on 106 consecutive patients with ARVC who received an ICD
based on one or more arrhythmic risk factors, such as syncope,
non-sustained VT, familial sudden death and inducibility at
programmed ventricular stimulation.35 During follow-up,
24% of patients had appropriate ICD interventions, 17 of
which (16%) were for VF or ventricular ﬂutter. All patients
survived to 48 months. Syncope was the most important pre-
dictor of ICD intervention but programmed ventricular stimu-
lation had a low accuracy for predicting ICD treatment. These
data add to current advice for ICD implantation in symptom-
atic patients, but the issue of primary prevention in asymptom-
atic patients remains a question for the future.
12. Dilated cardiomyopathy (DCM)
DCM, when deﬁned as LV dilatation and systolic impairment
in the absence of previous myocardial infarction, is one of the
common heart muscle diseases in developed countries.
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genetics in the aetiology of inherited and apparently acquired
forms of DCM has been a prominent feature. Tissue character-
isation imaging with CMR is another notable feature of recent
DCM research, with studies suggesting that it provides addi-
tional diagnostic and prognostic information. Patient manage-
ment continues to consist largely of standard symptomatic
and prognostic heart failure treatments, but recent work has be-
gun to identify the importance of aetiology in determining
management.
13. Aetiology
The difﬁculty in distinguishing between inherited and acquired
cases of DCM remains a major challenge as the proﬁle of clin-
ical ﬁndings rarely helps to identify aetiology. In cases of spo-
radic disease (i.e., in the absence of affected family members),
circumstantial evidence may suggest that causative cardiac in-
jury is inﬂammatory, toxic, load or heart rate dependent, or
due to metabolic abnormalities. However, recently published
data suggest that genetic susceptibility is often underestimated
in apparently sporadic disease. In the past, animal data have
demonstrated the importance of host genetic factors in deter-
mining susceptibility to cardiomyotrophic viral pathogens;36
in 2010, an association between myocarditis and common gene
variants was reported for the ﬁrst time in humans.37 In peri-
partum cardiomyopathy, studies demonstrated an association
of a chromosomal locus with peripartum DCM38 and the pres-
ence of undiagnosed DCM in ﬁrst-degree family members (3 of
10) of women diagnosed with peripartum DCM.39
Recent genetic studies have also challenged previously
accepted concepts of disease pathogenesis.40–54 A study of
100 unrelated patients with idiopathic DCM41 identiﬁed des-
mosomal gene sequence variants (some previously associated
with ARVC) in 18 patients, ﬁve of which were classiﬁed as
pathogenic. In limited co-segregation studies in two of the ped-
igrees, no mutant gene carriers fulﬁlled diagnostic criteria for
either ARVC or DCM, but frequent ventricular ectopy and/
or myopathic patterns of late gadolinium enhancement
(LGE) were detected in some mutation carriers with normal
echocardiograms. These ﬁndings illustrate the frequency of ge-
netic variants in patients with DCM and the heterogeneous
and often subtle manifestations of disease in relatives who car-
ry the same variant.
14. Advanced cardiac imaging and myocardial characterisation
Tissue characterisation, CMR’s unique contribution to non-
invasive imaging, can differentiate normal myocardium from
oedematous, ﬁbrotic and inﬁltrated myocardium and can
detect fatty change. In speciﬁc clinical situations, the proﬁle,
spatial distribution and temporal characteristics of tissue
abnormalities, can differentiate between the causes of cardiac
damage.55–57 Myocardial LGE after myocardial infarction is
typically subendocardial; in non-ischaemic DCM, LGE is de-
tected in at least one-third of cases58–60 and is typically mid-
wall or subepicardial, but neither the presence of LGE or its
localisation is speciﬁc for any particular aetiology.41,61,62 How-
ever, recently published work suggests that the presence of
LGE may be a marker of disease severity and is prognostically
important in some settings.58–60,63–65 Management strategiesthat incorporate LGE ﬁndings have not been formulated or
assessed.
CMR in the diagnosis of myocarditis, in particular with re-
spect to acute and chronic abnormalities in tissue characteris-
tics and their relation to disease progression to DCM and to
the development of heart failure.56,57,66
Larger studies are now needed to validate CMR diagnostic
criteria for myocarditis in a variety of clinical settings (e.g., in a
cohort with idiopathic DCM), and to establish whether CMR
ﬁndings have prognostic value.
15. Treatment
Guidelines for pharmacological and device therapies in heart
failure make little reference to aetiology-speciﬁc management.
In considering indications for device therapy (both ICD and
cardiac resynchronisation therapy), major national guidelines
suggest slightly different criteria for non-ischaemic than for
ischaemic heart failure that recognise the greater likelihood
that, on average, non-ischaemic DCM may have a better prog-
nosis.67–69
Recent work by Millat et al. identiﬁes some of the hazards
in assuming homogeneity among patients with DCM.45 They
demonstrated that nearly 10% of unrelated patients with
DCM had mutations in LAMIN A/C, a cause of DCM associ-
ated with particularly high risks of ventricular arrhythmias
and progressive conduction disease.70 Similar complications
are also common in the cardiomyopathy associated with myo-
tonic dystrophy71,72
More conventional imaging ﬁndings may also be important
in reﬁning device therapy.73–75 Recent publications describe
the prognostic importance of functional mitral regurgitation,
a feature of DCM related to LV geometry, contractility and
dyssynchrony.76,77 Rossi et al. demonstrate, in non-ischaemic
DCM, that functional mitral regurgitation is associated with
doubling of a combined end point of all-cause mortality hospi-
talisation and worsening heart failure.74
16. Genetics
Many of the inherited cardiac conditions for which a genetic
cause was ﬁrst detected were highly penetrant monogenic dis-
eases with a readily detectable cardiac phenotype amenable to
discovery approaches such as genetic linkage. In suitably sized
pedigrees with highly penetrant disease, linkage analysis can
provide statistical associations between a genetic locus/muta-
tion with a disease phenotype (i.e., a statistically robust co-seg-
regation expressed as a logarithmic or LOD score). This classic
genetic technique continues to deliver new genetic ﬁndings in
hereditary heart muscle disease.78,79
More restricted candidate approaches in mutation detec-
tion have predominated in recent research; advantages include
lower costs and an ability to study small families or individuals
with low penetrance disease. Candidate genes are selected for a
number of reasons that include membership in a gene group
already associated with disease (e.g., sarcomeric or desmo-
somal genes), an understanding that the gene’s function may
be important in the development of the phenotype (e.g., genes
involved in hypertrophic signalling) and particular features
identiﬁed in the disease state (e.g., differences in myocardial
gene expression proﬁles between affected and normal subjects).
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new candidate genes and heart muscle disease may be consid-
ered in at least three categories: descriptions of relative fre-
quencies of genetic abnormalities in genes known to cause a
speciﬁc disease;18,43,45,48 searches for sequence variants in
genes associated with one heart muscle disease in another
(cross-over or overlapping phenotypes)28,41,42,46–49,52,80 and
discovery of sequence variants in new candidates not previ-
ously associated with any cardiac disease.81,82
Until recently, largely empirical evidence has been used to
support candidate gene choice but selection methods inﬂuence
the pre-test probability that variants in the target gene are dis-
ease causing. More quantitative techniques for the identiﬁca-
tion of candidate genes have recently been described.83–85
Villard et al. performed genome-wide association studies on
pooled DNA samples obtained from patients with apparently
sporadic idiopathic DCM.83 Two single nuclear polymor-
phisms on chromosomes 1p36 and 10q26 were signiﬁcantly
associated with DCM. An interpretation of these data is that
these loci contain genes that play an important, but not causal,
role in the development of sporadic DCM. However, several
mutations in one of the candidate genes (BAG3, chromosome
10 locus) were identiﬁed in patients with familial DCM; several
of these mutations co-segregated with the familial phenotype.
It must be noted that it was unlikely that this study was de-
signed to identify candidate genetic causes of DCM; in any
case, none of the loci containing any of the many known
DCM genes were identiﬁed.
Remarkably, another methodological ﬁrst for cardiomyop-
athy also identiﬁed BAG3 as a cause of DCM. In the proband
and in three affected family members of a multigenerational
pedigree with autosomal dominant DCM, Norton et al. per-
formed both whole exon sequencing and a genome-wide
assessment of copy number variation (CNV).84 After exome
sequencing, none of the genetic variants identiﬁed in the pro-
band co-segregated with the disease. The high-density gen-
ome-wide CNV assay (said to have single-exon resolution)
detected a deletion encompassing exon 4 of BAG3 that co-seg-
regated with disease. As mutation detection strategies reliant
only on sequencing coding regions of the genome will fail to
detect CNVs caused by large deletions or insertions, future
CNV studies may yet tell us that large deletions in genes al-
ready associated with cardiomyopathies are an important
cause of these diseases.
Finally, using a more basic and inclusive approach to identi-
fying candidate genes, Neely et al. assessed the effects of car-
diac-speciﬁc ‘knock-down’ (with RNA-i) of more than 7000
genes in Drosophila reared under conditions of cardiac stress.85
The authors identiﬁed nearly 500 evolutionarily conserved
genes and pathways likely to have critical and conserved roles
in the cardiovascular system. Their ﬁndings identify many tar-
gets for future candidate gene studies; for example, altered car-
diac repolarisation is associated with a common polymorphism
in the human isoform of a gene associated with a DCM pheno-
type in Drosophila.
17. New technology
The term next-generation sequencing (NGS) refers to a number
of technologies that providemassively parallel, high throughputDNA sequencing. Technological advances in the preparation of
DNA before sequencing (enriching and labelling, for example),
in sequencing chemistry and in bioinformatics will result in
reduced costs and improvements in automation, accuracy and
coverage. Recently published reviews describe NGS in more
detail, and speciﬁcally with reference to inherited heart
disease.86,87
As the inherited heart muscle diseases have striking allelic
and locus heterogeneity (multiple mutations in many different
genes), NGS will enable a step-change in both research and
diagnostic applications of DNA sequencing. The ﬁrst few re-
ports of NGS being used to detect mutations in these condi-
tions were published in 2010 and 2011.84,88–90
18. Summary
As we approach the end of 2011 it is clear that the next few
years are going to be dominated by the application of new high
throughput genetic screening techniques, capable of screening
the entire exome or indeed genome. Understanding the data
generated by these techniques will require new and equally
sophisticated analysis of large and complex datasets, using a
systems biology approach with deeper phenotyping and
advanced modelling techniques that have the ﬂexibility for
continuous update, reﬁnement with discovery of new knowl-
edge. Exciting new developments that may also transform car-
diomyopathy research include those of infrastructure and
organisation (multi-centre collaborations) and spin-offs from
the ﬁeld of regenerative medicine research. For clinical
researchers that translate this information to the clinic the fo-
cus will however remain the same; namely improvement of
quality and quantity of life.
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